- $44.47m
- $54.27m
- $44.05m
Brief: Sanuwave Health Updates Second Quarter 2026 Guidance
Brief: Sanuwave Health - Forecasts Q2 2026 Revenue $11.1-$11.6 Million, Fy2026 Revenue $51.0-$55.0 Million - SEC Filing
SANUWAVE Health Q1 swings to operating loss as margins fall
Brief: Sanuwave Health Reports Preliminary Q1 2026 Revenue Of $9.6–$9.7 Million, Up 3-4% Year-Over-Year
Brief: Sanuwave Health Audit Committee Concludes Prior Financial Statements For Multiple Periods Should Not Be Relied Upon
Brief: Sanuwave Health Says 2026 Reimbursement For 97610 Code For Ultramist Products Is Unchanged
Brief: Sanuwave Health Announces Preliminary Revenue Results For The Third Quarter
Brief: Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
Brief: Sanuwave Announces Q2 Fy2025 Financial Results
Sanuwave Health Inc Expected To Post A Loss Of 9 Cents A Share: Earnings Preview
Brief: Sanuwave Health Announces Preliminary Revenue Results For The First Quarter 2025
Brief: Sanuwave Health To Uplist To The Nasdaq Global Market
Brief: SANUWAVE Health Announces 1-For-375 Reverse Stock Split
Brief: SANUWAVE Health Reports Stockholder Approval Of SEPA Merger At Special Meeting Of Stockholders
Brief: Sanuwave Health Enters Into Merger Deal With Sweat Equity Partners And Mercury Life Sciences-Affiliated Sep Acquisition Corp
Brief: SANUWAVE Announces Q3 Earnings
Brief: Sanuwave Health Q1 Revenue Rose 100 Percent To $3.2 Million
NanoVibronix Inc: Rises on licensing deal for ultrasound system
Brief: Sanuwave Completes Round Of Quality System And Technical File Audits